The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NWBO | -14.25% | -84.54% | -31.16% | -100% |
| S&P | +12.94% | +86.25% | +13.25% | +508% |
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
Will a 14-year clinical trial evaluating an immunotherapy for the most lethal form of brain cancer have a positive outcome?
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.20M | -44.0% |
| Gross Profit | -$0.32M | -94.5% |
| Gross Margin | -160.50% | -114.3% |
| Market Cap | $356.06M | -10.9% |
| Market Cap / Employee | $14.24M | 0.0% |
| Employees | 25 | 13.6% |
| Net Income | -$26.83M | -38.5% |
| EBITDA | -$13.80M | 3.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.56M | 55.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $36.25M | 23.7% |
| Short Term Debt | $40.80M | 40.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -298.81% | -54.5% |
| Return On Invested Capital | 106.89% | 23.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14.10M | -67.6% |
| Operating Free Cash Flow | -$13.89M | -68.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -4.42 | -3.21 | -3.36 | -3.49 | -32.16% |
| Price to Sales | 256.05 | 210.80 | 315.38 | 382.49 | 51.58% |
| Price to Tangible Book Value | -4.31 | -3.15 | -3.29 | -3.43 | -31.76% |
| Enterprise Value to EBITDA | -24.15 | -23.28 | -29.75 | -32.20 | -3.01% |
| Total Debt | $67.44M | $69.01M | $69.81M | $77.05M | 32.08% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
